H.U. Group Holdings, Inc. (MRCHF)

15,04 0,00 (0,00%) Börsenschluss: 10:09AM EDT

H.U. Group Holdings, Inc.

Shinjuku Mitsui Building
2-1-1 Nishishinjuku Shinjuku-ku
Tokyo 163-0408
Japan
81 3 5909 3335
https://www.hugp.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 5.437

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Shigekazu Takeuchi	Chairman, President & Group CEO	841,15k	N/A	1953
Ms. Atsuko Murakami	Executive Officer of Accounting & Finance and CFO	N/A	N/A	N/A
Mr. Kazuya Omi	Executive Officer & CTO	N/A	N/A	1979
Mr. Toshihiko Shimizu	Executive Officer & Chief Information Officer	N/A	N/A	1955
Mr. Shigeto Ohtsuki	Executive Officer of Human Resources	N/A	N/A	1961
Mr. Naoki Kitamura	Managing Executive Officer & Director	N/A	N/A	1970
Mr. Tadashi Hasegawa	Executive Officer and Head of Corporate Planning & Management Division	N/A	N/A	1970
Isao Tada	Division Head of Procurement Division	N/A	N/A	N/A
Mr. Hiroaki Kimura	Executive Officer of General Affairs	N/A	N/A	1961
Mr. Goki Ishikawa	Executive Officer of IVD	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally. The Lab Testing and Its Related Services segment collects specimens from medical offices, clinics, and hospitals, and conducts various tests at its laboratories. The segment also provides precision of the tests, pre-trial setup work, specimen collection and transport, measuring, result reports, and data management services for support in research and development of medicine. The In Vitro Diagnostics segment is involved in the provision of cerebrospinal fluid reagent, compatible with its automated chemiluminescent enzyme immunoassay system; development of blood-based reagents, as well as biomarkers specifically for neurodegenerative diseases, such as Alzheimer's. This segment also supplies key raw materials to global in-vitro diagnostics companies through a CDMO business model; offers Lumipulse, an automated chemiluminescence enzyme immunoassay system that offers reagents; and rapid diagnostics kits that serves as a platform for testing infectious diseases such as influenza and COVID-19. The Healthcare-related Services segment provides in-house sterilization services at the central supply rooms in hospitals and external sterilization at the sterilization centers; and offers operating and endoscopy room support, medical equipment maintenance and inspection, and logistics management and transportation services. This segment also engages in the sale of medical equipment, supplies, and consumables related to central supply and operating rooms; provision of home medical care and nursing services; and rental of nursing care equipment, such as wheelchairs and nursing beds. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.

Corporate Governance

H.U. Group Holdings, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 3. Die grundlegenden Scores sind Audit: 1, Vorstand: 1, Shareholderrechte: 8, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.